Working… Menu
Trial record 12 of 31 for:    ( Map: Albania )

An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03460782
Expanded Access Status : Available
First Posted : March 9, 2018
Last Update Posted : February 11, 2019
BioGene Pharmaceutical Inc.
Information provided by (Responsible Party):
Center Trials & Treatment

Brief Summary:
IPILIMUMAB Extended Access Program for patients who received chemotherapy and / or radiation therapy before the protocol, before or after the operation.

Condition or disease Intervention/treatment
Glioblastoma Glioma of Brain Biological: Ipilimumab

Detailed Description:

It is not yet known which protocols are a better treatment for glioblastoma or glioma.

The ipilimumab extended-access program for patients who received previous chemotherapy and / or radiation therapy by protocol, before ((for non-operable cases) or after the operation.

Monoclonal antibodies of CTLA-4, such as ipilimumab, may block tumor growth in different ways by targeting certain cells and activating the patient's immune system to fight the disease.

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients
Official Title: An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas

Intervention Details:
  • Biological: Ipilimumab

    Each patient receives Ipilimumab in regimen and dose according to the official manufacturer's instructions (IV 1 mg / kg every 6 weeks for maximum of 4 doses).

    Participation of the patient in the program must necessarily be agreed with the current treatment and contain a written agreement with the attending physician.

    This program is not covered by health insurance. For patients in the postoperative period to provide a mandatory conclusion of histology and molecular-genetic for the identified mutations and the type of tumor.

    Other Name: MDX-010

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Glioblastoma.
  • Glioma Brain.
  • Male or female subjects aged ≥18 years.
  • Histopathological evidence of glioblastoma or glioma.
  • Patients still alive must provide informed consent if required by local regulations
  • Maximal tumor diameter (including residual tumor and resection cavity if subjects had tumor resection rather than only stereotactic biopsy) up to 7cm or less.
  • Karnofsky performance status (Appendix 2) of ≥60.
  • Availability of a paraffin-embedded or frozen tumor-tissue block with a minimum of 0.5 cm2 and 5 unstained slides from the glioblastoma or glioma tissue specimen.
  • Not earlier than 35 days after surgery.
  • An interval of at least 2 week for stereotactic biopsy from the start of study treatment.
  • A contrast-enhanced MRI must be obtained within 7 days of the first dose of study treatment.
  • Adequate hematologic, hepatic, and renal function defined by test
  • Women must have a negative serum or urine pregnancy test before 24 hours of initiation of study drug.
  • Any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL to be defined as post-menopausal.

Women receiving ipilimumab will be instructed to adhere to contraception for a period of 35 weeks after the last dose of program.

  • Men receiving ipilimumab and who are sexually active will be instructed to adhere to contraception for a period of 39 weeks after the last dose of program.
  • Contraception is not required for men with documented vasectomy.
  • Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.
  • Women must not be breastfeeding.
  • Willing to and capable of providing written informed consent prior to any program related procedures.
  • Ability and willingness to comply scheduled visits, treatment plans, laboratory tests, and other program-related procedures.

Exclusion Criteria:

  • Prior systemic treatment anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways.
  • Planned participation in another study intended for therapy of glioma or glioblastoma.
  • Primary brainstem or spinal cord tumor.
  • Diffuse leptomeningeal gliomatosis.
  • Сonfirmed mutation of the IDH1/2 genes.
  • Stem or dendritic cell therapy 60 days before the program or 45 days after the last infusion of ipilimumab.
  • Systemic treatment with either immunosuppressive doses of corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 21 days of study drug administration.
  • Patients on a standard high-dose steroid taper after craniotomy or stereotactic biopsy may have received a higher dose of corticosteroids within 21 days of registration, however must be at a dose < 5 mg daily prednisone or bioequivalent per day within 7 days prior to initiation of study drug.
  • Patients requiring adrenal replacement with corticosteroids are eligible if the steroids are at doses ≤ 10 mg prednisone or bioequivalent per day in the absence of active autoimmune disease.
  • Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication) are allowed.
  • Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent.
  • Prior organ transplantation, including allogeneic stem cell transplantation.
  • Known history of, or any evidence of active, non-infectious pneumonitis within the last 5 years.
  • Known severe (NCI-CTCAE v4.03 Grade 3 or 4) infusion-related allergy or acute hypersensitivity reaction attributed to any monoclonal antibody, any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma).
  • Unable tolerate an MRI, or have a contraindication to MRI.
  • Active infection requiring systemic therapy.
  • Positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome.
  • Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus (HCV antibody) indicating acute or chronic infection.
  • Vaccination within 5 weeks of the first dose of study drug and while on trials is prohibited except for administration of inactivated vaccines.

ATTENTION: Seasonal influenza vaccines for injection are live attenuated vaccines, and are not allowed.

  • Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ NY Heart Association - CC II), or serious cardiac arrhythmia requiring medication.
  • All other unstable, severe, or chronic medical or psychiatric conditions including colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis, recent (within the past year) or active suicidal idea in behavior, or laboratory abnormalities that may increase the risk associated with program or judgment of the investigator, would make the patient participation impossible.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03460782

Layout table for location contacts
Contact: Daniel M Cherrett 508 786 670 ext 94
Contact: Elizabeth Wonemeyer 443 665 380

Layout table for location information
University "Mother Theresa" Hospital Center; Oncology Department
Tirana, Albania, 1000
Bosnia and Herzegovina
University Clinical Center of the Republic of Srpska
Banja Luka, Bosnia and Herzegovina, 78000
Complex Oncology Center
Plovdiv, Bulgaria, 4004
Clinical Hospital Osijek; Dept For Oncology & Radiotherapy
Osijek, Croatia, 31000
Institut of Oncology Al. Trestioreanu Bucharest; Oncology
Bucharest,, Romania, 022338
Russian Federation
Regional Oncology Hospital
Irkutsk, Russian Federation, 664035
Rostov Cancer Research Institute
Rostov-on-Don, Russian Federation, 344037
Primorsky Regional Oncology Center
Vladivostok, Russian Federation, 690069
Clinical Hospital Center Bezanijska kosa; Clinic for Oncology
Belgrade, Serbia, 11 000
Inselspital Bern; Medizinische Onkologie
Bern, Switzerland, 3010
Stadtspital Triemli; Frauenklinik
Zürich, Switzerland, 8063
Sponsors and Collaborators
Center Trials & Treatment
BioGene Pharmaceutical Inc.

Layout table for additonal information
Responsible Party: Center Trials & Treatment Identifier: NCT03460782     History of Changes
Other Study ID Numbers: PST-9-IP
First Posted: March 9, 2018    Key Record Dates
Last Update Posted: February 11, 2019
Last Verified: February 2019
Keywords provided by Center Trials & Treatment:
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents, Immunological
Antineoplastic Agents